Gnathostomiasis is a parasitic infection caused by the larvae of the genus Gnathostoma. These parasitic worms typically infect fish and other intermediate hosts, with humans acting as accidental hosts. The primary mode of transmission to humans is through the consumption of raw or undercooked freshwater fish, amphibians, or reptiles containing infective larvae. Once ingested, the larvae migrate through the gastrointestinal tract, penetrate the intestinal wall, and can travel to various tissues, causing a range of symptoms. Clinical manifestations of gnathostomiasis vary depending on the migration of larvae. Early symptoms may include migratory, subcutaneous swellings known as "creeping eruptions" or "larva migrans," as the parasites move beneath the skin. This phenomenon is accompanied by itching, redness, and discomfort. In more severe cases, larvae may invade internal organs, leading to visceral gnathostomiasis. Symptoms can include abdominal pain, vomiting, fever, and neurological complications if larvae reach the central nervous system. Diagnosis of gnathostomiasis often relies on clinical presentation, travel history, and laboratory tests. Treatment typically involves anthelminthic drugs such as albendazole or ivermectin, along with supportive care for complications.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain